These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21618420)

  • 41. Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL).
    Mejía-Aranguré E; Reyes-López A; Juárez-Villegas LE; Hernández-Olivares YO; Saucedo-Campos AD; Hernández-Pliego G; Martínez-Valverde S; Barajas-Nava LA; Garduño-Espinosa J
    BMC Health Serv Res; 2022 Dec; 22(1):1522. PubMed ID: 36517861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacoeconomic considerations in treating patients with acute leukaemia.
    Jønsson V; Hansen MM; Ljungman P; Kaasa S
    Pharmacoeconomics; 1999 Feb; 15(2):167-78. PubMed ID: 10351190
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug pricing should depend on shared values.
    Ramsey S
    Nature; 2017 Dec; 552(7685):S78. PubMed ID: 29293242
    [No Abstract]   [Full Text] [Related]  

  • 44. Commentary: demonstrating cost-effectiveness in pediatric psychology.
    McGrady ME
    J Pediatr Psychol; 2014 Jul; 39(6):602-11. PubMed ID: 24752732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Establishing Cost-effective Strategies for Predicting Outcomes of Pediatric Leukemia.
    Jain A
    J Pediatr Hematol Oncol; 2020 Oct; 42(7):451. PubMed ID: 32852397
    [No Abstract]   [Full Text] [Related]  

  • 46. Costs and cost-effectiveness of new technologies in cancer.
    Waters TM
    Cancer Treat Res; 1998; 97():25-36. PubMed ID: 9711407
    [No Abstract]   [Full Text] [Related]  

  • 47. NEW MEDICAL TECHNOLOGY AND COST EFFECTIVENESS.
    Anand LCA
    Med J Armed Forces India; 1996 Jul; 52(3):181-183. PubMed ID: 28769382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adding anticholinergics in acute childhood and adolescent asthma is cost effective.
    BMJ; 1999 Dec; 319(7223):G. PubMed ID: 10582969
    [No Abstract]   [Full Text] [Related]  

  • 49. Including Both Costs and Effects--The Challenge of Using Cost-Effectiveness Data in National-Level Policy-Making: A Response to Recent Commentaries.
    Eckard N; Janzon M; Levin LÅ
    Int J Health Policy Manag; 2015 Jul; 4(8):565-6. PubMed ID: 26340402
    [No Abstract]   [Full Text] [Related]  

  • 50. Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood.
    Rae C; Furlong W; Jankovic M; Moghrabi A; Naqvi A; Sala A; Samson Y; DePauw S; Feeny D; Barr R
    Eur J Cancer Care (Engl); 2014 Nov; 23(6):779-85. PubMed ID: 24393150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.
    Tong WH; van der Sluis IM; Alleman CJ; van Litsenburg RR; Kaspers GJ; Pieters R; Uyl-de Groot CA
    Haematologica; 2013 May; 98(5):753-9. PubMed ID: 23403311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Health status utilities in pediatrics: a systematic review of acute lymphoblastic leukemia.
    van Litsenburg RR; Kunst A; Huisman J; Ket JC; Kaspers GJ; Gemke RJ
    Med Decis Making; 2014 Jan; 34(1):21-32. PubMed ID: 23886678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002.
    Gatta G; Rossi S; Foschi R; Trama A; Marcos-Gragera R; Pastore G; Peris-Bonet R; Stiller C; Capocaccia R;
    Haematologica; 2013 May; 98(5):744-52. PubMed ID: 23403323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Effects of Hospital Length of Stay on Readmissions for Children With Newly Diagnosed Acute Lymphoblastic Leukemia.
    Wedekind MF; Dennis R; Sturm M; Koch T; Stanek J; O'Brien SH
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):329-33. PubMed ID: 26989914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden.
    Katz AJ; Chia VM; Schoonen WM; Kelsh MA
    Cancer Causes Control; 2015 Nov; 26(11):1627-42. PubMed ID: 26376890
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
    Zugmaier G; Klinger M; Schmidt M; Subklewe M
    Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.
    Dhédin N; Huynh A; Maury S; Tabrizi R; Beldjord K; Asnafi V; Thomas X; Chevallier P; Nguyen S; Coiteux V; Bourhis JH; Hichri Y; Escoffre-Barbe M; Reman O; Graux C; Chalandon Y; Blaise D; Schanz U; Lhéritier V; Cahn JY; Dombret H; Ifrah N;
    Blood; 2015 Apr; 125(16):2486-96; quiz 2586. PubMed ID: 25587040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration.
    August KJ; Miller WP; Dalton A; Shinnick S
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):e283-6. PubMed ID: 23619117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How I treat relapsed childhood acute lymphoblastic leukemia.
    Locatelli F; Schrappe M; Bernardo ME; Rutella S
    Blood; 2012 Oct; 120(14):2807-16. PubMed ID: 22896001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health-related quality of life and utility scores in short-term survivors of pediatric acute lymphoblastic leukemia.
    van Litsenburg RR; Huisman J; Raat H; Kaspers GJ; Gemke RJ
    Qual Life Res; 2013 Apr; 22(3):677-81. PubMed ID: 22547048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.